ArticleCancer research2010
Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Focused Modulation of Brain Activity: A Narrative Review.Biomedicines · 2025Review
- A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients.FEBS open bio · 2019Article
- Targeted Diphtheria Toxin-Based Therapy: A Review Article.Frontiers in microbiology · 2019Review
- Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma.Cancer management and research · 2019Article
- Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy.Journal of theoretical biology · 2017Article
- Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.Scientific reports · 2017Article
- Effect of rs11614913 Polymorphism on Mature miR196a2 Expression and its Target Gene HOXC8 Expression in Human Glioma.Journal of molecular neuroscience : MN · 2017Article
- Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.Frontiers in oncology · 2017Review
- Development of targeted therapies in treatment of glioblastoma.Cancer biology & medicine · 2015Review
- Temozolomide nanoparticles for targeted glioblastoma therapy.ACS applied materials & interfaces · 2015Article
- Circulating microRNA biomarkers for glioma and predicting response to therapy.Molecular neurobiology · 2014Review
- Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin.Advanced drug delivery reviews · 2013Review
- Strategies for overcoming the blood-brain barrier for the treatment of brain metastases.CNS oncology · 2013Review
- Imaging tumor burden in the brain with 89Zr-transferrin.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Article
- Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma.Oncotarget · 2012Review
- Article
- The intracellular trafficking pathway of transferrin.Biochimica et biophysica acta · 2012Review
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer.Biochimica et biophysica acta · 2012Review
- Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor with median survival of only 12 to 15 months under the current standard of care. To both increase tumor specificity and decrease nonspecific side effects, recent experimental strategies in the treatment of GBM have focused on targeting cell surface receptors, including the transferrin (Tf) receptor, that are overexpressed in many cancers. A major limitation of Tf-based therapeutics is the short association of Tf within the cell to deliver its payload. We previously developed two mutant Tf molecules, K206E/R632A Tf and K206E/K534A Tf, in which iron is locked into each of the two homologous lobes. Relative to wild-type Tf, we showed enhanced delivery of diphtheria toxin (DT) from these mutants to a monolayer culture of HeLa cells. Here, we extend the application of our Tf mutants to the treatment of GBM. In vitro treatment of Tf mutants to a monolayer culture of glioma cells showed enhanced cellular association as well as enhanced delivery of conjugated DT. Treatment of GBM xenografts with mutant Tf-conjugated DT resulted in pronounced regression in vivo, indicating their potential use as drug carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.